Macular degeneration

This trial is testing an experimental eye gel called BETA-TT8 for people with wet age-related macular degeneration (AMD), a condition that causes rapid vision loss. The gel is applied to the eye up to three times daily for 12 weeks, and standard injections remain available if nee…

Researchers are testing an experimental drug called OLN324 against ranibizumab, a standard treatment for wet age-related macular degeneration (nAMD). The trial enrolls about 400 adults aged 50 and older who have not yet received treatment for active wet AMD in the study eye. Part…

Researchers are testing an experimental drug called OLN324 against the standard treatment, aflibercept, in adults with wet age-related macular degeneration. About 500 people aged 50 and older who have not yet received treatment for this condition will take part. Both drugs are gi…

This trial tests an experimental drug called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. Researchers compare two doses of VIS-101 against aflibercept, a standard treatment, to see if VIS-…

This study tests a non-invasive laser treatment called photobiomodulation for people with early age-related macular degeneration (AMD) who have a specific type of deposit in the eye called reticular pseudodrusen. The treatment uses low-energy light to stimulate cells and reduce i…

This trial tests a gene therapy called PST-611 in people aged 65 and older with geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. PST-611 is a DNA plasmid injected into the eye muscle that instructs cells to produce human transferri…

This study tests whether a remote dietary program can help people with early to intermediate age-related macular degeneration (AMD) lower their blood sugar and increase protective nutrients called carotenoids. About 32 participants will receive coaching to improve their eating ha…

This Phase 2a trial tests SCAI-005 eye drops in 50 adults with wet age-related macular degeneration (AMD). Participants will receive either a low dose, high dose, or placebo drops three times daily. The study aims to see if the drops can reduce retinal swelling and control the di…

This early study tests whether stimulating a nerve cluster behind the cheekbone (the pterygopalatine ganglion) is safe and doable for people with geographic atrophy, a severe form of age-related macular degeneration that causes blind spots. Sixty-two adults will receive either re…

This study tests a new medicine called AIV007 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. About 35 participants will receive either AIV007 or the standard treatment Eylea. The goal is to see if AIV007 can improve vision and reduce t…

This early-stage trial tests whether transplanting lab-grown retinal cells (made from stem cells) into the eye is safe for people with late-stage age-related macular degeneration. Nine participants will receive the cell transplant and be monitored for side effects and any improve…

This study tests a new, non-invasive treatment for dry age-related macular degeneration (AMD), a common cause of vision loss in older adults. About 94 people aged 50 and older with dry AMD will use a red-light device at home twice daily for three months. Researchers will check if…

This study tests an experimental pill (EG-301) taken daily for at least 6 months in 90 people with dry age-related macular degeneration (AMD) and geographic atrophy. Participants are randomly assigned to receive either standard AREDS2 supplements alone or AREDS2 plus EG-301. The …

This study tests faricimab, a drug injected into the eye, for people with type 3 wet age-related macular degeneration (AMD), a condition that can cause rapid vision loss. Over 76 weeks, 30 participants will receive initial monthly doses, then a personalized schedule where injecti…

This trial tests an artificial intelligence system called QiLin that helps doctors decide when to give anti-VEGF injections for retinal diseases like wet AMD, DME, and RVO. About 200 patients who have completed initial treatment will be randomly assigned to have their doctor use …

This study will develop and test an artificial intelligence system to detect common eye diseases like glaucoma, cataracts, and diabetic retinopathy using 15,000 existing eye images from Costa Rican patients. The goal is to create a tool that works accurately for local populations…

This study will test a new, non-invasive eye scanner called wide field OCTA in 200 people with various eye diseases, including age-related macular degeneration, diabetic retinopathy, and dry eye. The goal is to see if this device can provide better images of blood vessels in the …

This study will test a new artificial intelligence (AI) system that reads eye scans (OCT) to diagnose common blinding eye diseases like diabetic retinopathy, glaucoma, and age-related macular degeneration. Researchers will collect 2000 eye scans from patients at Peking Union Medi…

This early study tests whether a wearable ultrasound device can safely stimulate retinal cells and help restore vision in people with age-related macular degeneration or retinitis pigmentosa. Five participants will receive short ultrasound pulses while reporting what they see. Th…

Doctors use anti-VEGF injections to treat retinal diseases such as age-related macular degeneration and diabetic macular edema, and patients often need these shots for years. During each injection, a small tool holds the eyelids open, stretching the upper lid. Researchers want to…

This early-stage trial is evaluating the safety, tolerability, and how the body absorbs PAN-90806, an experimental eye drop being developed for wet age-related macular degeneration (AMD), a leading cause of vision loss. Healthy adults aged 18 to 50 will receive either PAN-90806 o…

This study looks at whether shifting text to a different part of the eye can help people with central vision loss read faster and more accurately. Researchers will test 100 participants with conditions like macular degeneration using various reading tasks. The goal is to find bet…

This study aims to develop new methods to help veterans with vision loss caused by age-related macular degeneration. About 20 veterans aged 50 and older with reduced vision will take part. Researchers will measure how well they recognize objects and how their brains respond befor…

This study tests whether a personalized care approach helps patients with chronic macular diseases (like wet age-related macular degeneration and diabetic macular edema) attend their regular eye injection appointments. Many patients skip these vital treatments, risking further vi…

This study aims to see if elderly patients with age-related macular degeneration (AMD) find a new web-based eye-tracking system easy and acceptable to use at home. The system is designed to help patients monitor their vision without frequent clinic visits. Thirty patients aged 55…

This study will look at 30 people with macular dystrophy to see how different eye tests—like OCT scans, mfERG, and standard vision tests—relate to each other. The goal is to better understand how these tests can track vision changes. No treatment is being tested; this is purely a…